title: Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.
abstract: Associations between HLA class I antigen expression and the efficacy of a melanoma vaccine (Melacine; Corixa Corp.) were initially described in stage IV melanoma. Similar associations were observed in S9035, a phase III adjuvant trial evaluating Melacine for 2 years compared with observation in patients with stage II melanoma. This report provides long-term results. The effects of treatment on relapse-free survival (RFS) and overall survival (OS) were evaluated, and prespecified analyses investigated associations between treatment and HLA expression. Multivariable analyses were adjusted for tumor thickness, ulceration and site, method of nodal staging, and sex. P = 0.01 was considered statistically significant in subset analyses to account for multiple comparisons. For the entire study population of 689 patients, there were no significant differences in RFS or OS by treatment arm. HLA serotyping was performed on 553 (80%) patients (vaccine, 294; observation, 259). Among the subpopulation with HLA-A2 and/or HLA-Cw3 serotype, vaccine arm patients (n = 178) had marginally improved RFS (adjusted P = 0.02) and significantly improved OS compared with observation arm patients (n = 145), with 10-year OS of 75% and 63%, respectively [hazard ratio (HR), 0.62; 99% confidence interval (CI), 0.37-1.02; P = 0.01]. There was no impact of HLA-A2 and/or HLA-Cw3 expression on observation arm patients. An analysis of mature data from S9035 indicates a significant OS benefit from adjuvant vaccine therapy for patients with HLA-A2- and/or HLA-Cw3-expressing melanoma. The possibility of interactions between HLA type and outcome should be considered in future immunotherapy trials. Further investigations of melanoma-associated antigens present in Melacine and presented by HLA-A2 and HLA-Cw3 may be warranted.
authors.affiliation: Division of Surgical Oncology, The Ohio State University, Columbus, Ohio. william.carson@osumc.edu.
authors.forename: William E
authors.initials: WE
authors.lastname: Carson
authors.affiliation: SWOG Statistical Center, Seattle, Washington.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Unger
authors.affiliation: Vanderbilt University, Nashville, Tennessee.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Sosman
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
authors.forename: Lawrence E
authors.initials: LE
authors.lastname: Flaherty
authors.affiliation: Cleveland Clinic Foundation, Cleveland, Ohio.
authors.forename: Ralph J
authors.initials: RJ
authors.lastname: Tuthill
authors.affiliation: Division of Surgical Oncology, The Ohio State University, Columbus, Ohio.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Porter
authors.affiliation: Seattle Cancer Care Alliance, Seattle, Washington.
authors.forename: John A
authors.initials: JA
authors.lastname: Thompson
authors.affiliation: Los Angeles County Department of Health Services, University of Southern California, Los Angeles, California.
authors.forename: Raymond A
authors.initials: RA
authors.lastname: Kempf
authors.affiliation: SWOG Statistical Center, Seattle, Washington.
authors.forename: Megan
authors.initials: M
authors.lastname: Othus
authors.affiliation: University of California Los Angeles, Los Angeles, California.
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
authors.affiliation: H. Lee Moffitt Cancer Center, Tampa, Florida.
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D015395:Histocompatibility Antigens Class I / Q000097:blood*; D006650:Histocompatibility Testing; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; C116434:Melacine